MedElevator
Войти в исследования Clinical genitourinary cancer · 2026
Clinical Characteristics and Predictive Factors of Symptomatic Skeletal Events in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Denosumab.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Inaba Yuzo, Urabe Fumihiko, Imai Yu, Nakano Juria, Fujiwara Kensuke, Hashimoto Masaki, Koike Yuhei, Iwamoto Yuya, Hara Shuhei, Miyajima Keiichiro, Fukuokaya Wataru, Iwatani Kosuke, Atsuta Mahito, Murakami Masaya, Tashiro Kojiro, Yamaguchi Masato, Shimomura Tatsuya, Miki Jun, Kimura Takahiro, JIKEI-YAYOI Collaborative Group
Аннотация
BACKGROUND: Skeletal-related events are significant complications in prostate cancer patients with bone metastases. While bone-modifying agents are established in metastatic castration-resistant prostate cancer (mCRPC), their role in metastatic castration-sensitive prostate cancer (mCSPC) remains unclear. This study characterized symptomatic skeletal events (SSEs) and identified factors predicting their onset in mCSPC patients treated with denosumab.
METHODS: We retrospectively analyzed 318 mCSPC patients with bone metastases who received denosumab between 2015 and 2024. The primary endpoint was the probability of SSE occurrence, defined as symptomatic pathologic fracture, spinal cord compression, symptoms requiring orthopedic surgery, or external beam radiotherapy (EBRT) due to bone complications. Predictive factors were assessed using multivariate Cox regression and logistic regression analyses. The optimal serum alkaline phosphatase (ALP) cutoff for predicting SSEs was determined with receiver operating characteristic (ROC) analysis.
RESULTS: Over a median follow-up of 25 months, 32 patients (10.1%) developed SSEs, most commonly symptoms requiring EBRT (7.9%). The 3-year probability of SSE occurrence was 15.4%. Multivariate analysis identified elevated ALP as an independent predictor of SSEs (hazard ratio per 50-U increase: 1.03; 95% confidence interval, 1.01-1.04; P = .002). The ROC-derived ALP cutoff of 127.75 U/L was significantly associated with increased SSE risk. The most common reasons for denosumab discontinuation were death (19.0%) and osteonecrosis of the jaw (19.0%).
CONCLUSIONS: In this real-world mCSPC cohort, SSEs occurred in ∼15% of patients within 3 years of denosumab initiation. Elevated ALP was a significant predictor, supporting the need for individualized bone management strategies in mCSPC.
METHODS: We retrospectively analyzed 318 mCSPC patients with bone metastases who received denosumab between 2015 and 2024. The primary endpoint was the probability of SSE occurrence, defined as symptomatic pathologic fracture, spinal cord compression, symptoms requiring orthopedic surgery, or external beam radiotherapy (EBRT) due to bone complications. Predictive factors were assessed using multivariate Cox regression and logistic regression analyses. The optimal serum alkaline phosphatase (ALP) cutoff for predicting SSEs was determined with receiver operating characteristic (ROC) analysis.
RESULTS: Over a median follow-up of 25 months, 32 patients (10.1%) developed SSEs, most commonly symptoms requiring EBRT (7.9%). The 3-year probability of SSE occurrence was 15.4%. Multivariate analysis identified elevated ALP as an independent predictor of SSEs (hazard ratio per 50-U increase: 1.03; 95% confidence interval, 1.01-1.04; P = .002). The ROC-derived ALP cutoff of 127.75 U/L was significantly associated with increased SSE risk. The most common reasons for denosumab discontinuation were death (19.0%) and osteonecrosis of the jaw (19.0%).
CONCLUSIONS: In this real-world mCSPC cohort, SSEs occurred in ∼15% of patients within 3 years of denosumab initiation. Elevated ALP was a significant predictor, supporting the need for individualized bone management strategies in mCSPC.